Pretreatment Computed Tomography-Defined Sarcopenia, Treatment-Associated Muscle Loss, and Survival in Patients With Cervical Cancer: A Systematic Review and Meta-Analysis.

IF 5.9 2区医学 Q1 NUTRITION & DIETETICS

Nutrition reviews Pub Date : 2024-09-28 DOI:10.1093/nutrit/nuae130

Mengxing Tian, Huiting Xu, Hongbin Wang, Huifen Wang, Zhu Dai, Chenchen Ding, Huan Guo, Xin Jin

{"title":"Pretreatment Computed Tomography-Defined Sarcopenia, Treatment-Associated Muscle Loss, and Survival in Patients With Cervical Cancer: A Systematic Review and Meta-Analysis.","authors":"Mengxing Tian, Huiting Xu, Hongbin Wang, Huifen Wang, Zhu Dai, Chenchen Ding, Huan Guo, Xin Jin","doi":"10.1093/nutrit/nuae130","DOIUrl":null,"url":null,"abstract":"Context: Sarcopenia has been identified as a potential predictor of poor prognosis in various types of cancer. However, the impact of pretreatment sarcopenia and the reduction of skeletal muscle mass during treatment on survival outcomes of patients with cervical cancer is still not well understood.Objective: This meta-analysis was conducted to investigate the impact of pretreatment sarcopenia and treatment-associated muscle loss on survival outcomes in patients with cervical cancer.Data sources: The PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched for studies exploring the relationship between muscle loss and the prognosis of cervical cancer until January 1, 2023.Data extraction: The hazard ratios (HRs) and 95% CIs for overall survival (OS) and progression-free survival (PFS) were extracted.Data analysis: The data were analyzed using R software. The studies' quality was assessed using the Quality in Prognostic Studies tool. Twelve observational studies involving 1498 patients with cervical cancer were included in the analysis, with a prevalence of sarcopenia ranging from 24.8% to 57.5%. Sarcopenia was an independent predictor of poor OS (HR, 1.68; 95% CI, 1.28-2.21; P < .01) and PFS (HR, 1.53; 95% CI, 1.19-1.98; P < .01) in patients with cervical cancer. Additionally, the decrease in skeletal muscle during treatment was also significantly related to the OS (HR, 4.46; 95% CI, 2.87-6.94; P < .01) and PFS (HR, 2.89; 95% CI. 1.83-4.55; P < .01).Conclusions: The prevalence of pretreatment sarcopenia was high among patients with cervical cancer. Pretreatment sarcopenia and skeletal muscle loss during treatment both negatively affected prognosis in cervical cancer.","PeriodicalId":19469,"journal":{"name":"Nutrition reviews","volume":null,"pages":null},"PeriodicalIF":5.9000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/nutrit/nuae130","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Context: Sarcopenia has been identified as a potential predictor of poor prognosis in various types of cancer. However, the impact of pretreatment sarcopenia and the reduction of skeletal muscle mass during treatment on survival outcomes of patients with cervical cancer is still not well understood.

Objective: This meta-analysis was conducted to investigate the impact of pretreatment sarcopenia and treatment-associated muscle loss on survival outcomes in patients with cervical cancer.

Data sources: The PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched for studies exploring the relationship between muscle loss and the prognosis of cervical cancer until January 1, 2023.

Data extraction: The hazard ratios (HRs) and 95% CIs for overall survival (OS) and progression-free survival (PFS) were extracted.

Data analysis: The data were analyzed using R software. The studies' quality was assessed using the Quality in Prognostic Studies tool. Twelve observational studies involving 1498 patients with cervical cancer were included in the analysis, with a prevalence of sarcopenia ranging from 24.8% to 57.5%. Sarcopenia was an independent predictor of poor OS (HR, 1.68; 95% CI, 1.28-2.21; P < .01) and PFS (HR, 1.53; 95% CI, 1.19-1.98; P < .01) in patients with cervical cancer. Additionally, the decrease in skeletal muscle during treatment was also significantly related to the OS (HR, 4.46; 95% CI, 2.87-6.94; P < .01) and PFS (HR, 2.89; 95% CI. 1.83-4.55; P < .01).

Conclusions: The prevalence of pretreatment sarcopenia was high among patients with cervical cancer. Pretreatment sarcopenia and skeletal muscle loss during treatment both negatively affected prognosis in cervical cancer.

查看原文本刊更多论文

宫颈癌患者治疗前计算机断层扫描确定的肌肉疏松症、治疗相关肌肉损失与生存率：系统回顾与元分析》。

背景：肌肉疏松症被认为是多种癌症预后不良的潜在预测因素。然而，治疗前肌少症和治疗期间骨骼肌质量减少对宫颈癌患者生存预后的影响仍不甚了解：本荟萃分析旨在研究治疗前肌少症和治疗期间肌肉减少对宫颈癌患者生存结果的影响：数据提取：在PubMed、EMBASE、Web of Science和Cochrane Library数据库中检索了截至2023年1月1日有关肌肉减少与宫颈癌预后关系的研究：提取总生存期（OS）和无进展生存期（PFS）的危险比（HRs）和95% CIs：数据分析：使用R软件对数据进行分析。研究质量采用预后研究质量工具进行评估。分析共纳入了12项观察性研究，涉及1498名宫颈癌患者，其中肌肉疏松症的患病率从24.8%到57.5%不等。肌营养不良症是预测较差OS的一个独立因素（HR，1.68；95% CI，1.28-2.21；P 结论：肌营养不良症是预测较差OS的一个独立因素（HR，1.68；95% CI，1.28-2.21）：宫颈癌患者在治疗前出现肌肉疏松症的比例很高。治疗前的肌肉疏松症和治疗期间的骨骼肌流失都会对宫颈癌的预后产生负面影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutrition reviews 医学-营养学

CiteScore

12.20

自引率

1.60%

发文量

121

审稿时长

6-12 weeks

期刊介绍： Nutrition Reviews is a highly cited, monthly, international, peer-reviewed journal that specializes in the publication of authoritative and critical literature reviews on current and emerging topics in nutrition science, food science, clinical nutrition, and nutrition policy. Readers of Nutrition Reviews include nutrition scientists, biomedical researchers, clinical and dietetic practitioners, and advanced students of nutrition.